Register Login

Orchestra Biomed Holdings Inc (OBIO)

(75% Positive) ORCHESTRA BIOMED HOLDINGS, INC. (OBIO) Announces Enrollment Update for enrollment Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 28, 2025, 12:14 p.m.

    📋 ORCHESTRA BIOMED HOLDINGS, INC. (OBIO) - Clinical Trial Update

    Filing Date: 2025-10-28

    Accepted: 2025-10-28 08:12:47

    Event Type: Clinical Trial Update

    Event Details:

    Orchestra Biomed Holdings Inc (OBIO) Announces Clinical Trial Update Orchestra Biomed Holdings Inc (OBIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: enrollment
    • Collaboration: Virtue®
    • Updated Timeline: October 28, 2025

    🔬 Clinical Development Pipeline (ORCHESTRA BIOMED HOLDINGS, INC.):

    Product Type Development Stage Therapeutic Area Source
    AGENT™ Paclitaxel Drug-Coated Balloon DEVICE Approved Coronary Artery Disease ClinicalTrials.gov
    Virtue Sirolimus AngioInfusion Balloon DEVICE Approved Coronary Artery Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Orchestra Biomed Holdings Inc
    • CIK: 0001814114
    • Ticker Symbol: OBIO
    • Period End Date: 2025-10-24
    • Document Type: 8-K

Search

News categories